Expression of chemokine receptor CXCR4 in tumor cells and content of CXCL12+-fibroblasts in endometrioid carcinoma of endometrium

Authors

  • L.G. Buchynska R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.M. Movchan National Cancer Institute of the Ministry of Health of Ukraine, Kyiv 03022, Ukraine
  • N.P. Iurchenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16240

Keywords:

chemokine, chemokine receptor, CXCL12, CXCL12 expressing-fibroblasts, CXCR4, endometrioid carcinoma

Abstract

Summary. Background: The expression of the CXCL12 chemokine and its receptor CXCR4 in the stromal component of the tumor plays an important role in tumor cell migration, proliferation, inhibition of apoptosis and determination of invasive and metastatic potential of malignant neoplasms of various genesis. The significance of CXCL12 and CXCR4 expression in endometrial tumor cells for cancer progression is not fully understood. Aim: To evaluate the content of CXCL12+-fibroblasts and expression of CXCL12 and CXCR4 in endometrial cancer cells, depending on the tumor stage. Materials and Methods: Surgical material of 45 patients with endometrioid carcinoma of the endometrium (ECE) of the stages I–II and III was studied using morphological and immunohistochemical methods. Results: In ECE of stage I–II CXCR4 expression was lower (43.3 ± 4.2%) while CXCL12 expression was higher (33.6 ± 2.4%) compared with the corresponding indices​​ in ECE of stage III (63.6 ± 3.5%, 24.5 ± 1.9%, respectively, p < 0.05). In ECE of stage III, high expression of CXCR4 (> Me) and low CXCL12 (< Me) was observed in 80% of samples; these tumors invaded more than 1/2 of the myometrium. There was a positive correlation between the depth of tumor invasion in the myometrium and the presence of metastases and CXCR4 expression in tumor cells (R = 0.5 and R = 0.4, respectively, p < 0.05) and the negative correlation with the expression of CXCL12 (R = –0.6 and R = –0.3, respectively, p < 0.05). In tumors that deeply invaded the myometrium, a high number of the CXCL12+-fibroblasts (> Me) (14.9 ± 1.3%) was detected. Conclusion: The obtained data reflect the communication of the immunosuppressive factor of the tumor microenvironment, i.e. CXCL12+-fibroblasts and CXCR4 expressing tumor cells. We suggest that the aggressiveness of ECE is determined by the combined effect of these two factors.

References

Shi Yi, Riese DJ, Shen J. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol 2020; 11: 574667.

Meng W, Xue S, Chen Y. The role of CXCL12 in tumor microenvironment. Gene. doi:10.1016/j.gene. 2017.10.015.

Liu W, Yang Z, Lu W, et al. Chemokines and chemokine receptors: A new strategy for breast cancer therapy. Cancer Med 2020; 9: 3786–99.

Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The emerging role of the microenvironment in endometrial cancer. Cancers 2018; 10: 408; doi:10.3390/cancers10110408.

Zielińska KA, Katanaev VL. The signaling duo CXCL12 and CXCR4/chemokine fuel for breast cancer tumorigenesis. Cancers (Basel) 2020; 12: 3071. doi: 10.3390/cancers12103071.

Fulton AM. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 2009; 11: 125–31.

Long P, Sun F, Ma Y, et al. Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer. Tumour Biol 2016; 37: 7473–80.

Kircher M, Herhaus P, Schottelius M, et al.CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med 2018; 32: 503–51.

Wu W, Qian L, Chen X, et al. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. J Clin Exp Pathol 2015; 8: 13217–24.

Stanisavljević L, Aßmus J, Storli K, et al. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer. Tumour Biol 2016; 37: 7441–52.

Samarendra H, Jones K, Petrinic T, et al. A meta-analysis of CXCL12 expression for cancer prognosis. Br J Cancer 2017; 117: 124–35.

Walentowicz-Sadlecka M, Sadlecki P, Bodnar M, et al. Stromal Derived Factor-1 (SDF-1) and іts receptors CXCR4 and CXCR7 in endometrial cancer patients. PLoS One 2014; 9: e84629.

Teng F, Tian WY, Wang YM, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 2016; 9: 8.

Kodama J, Hasengaowa, Kusumoto T, et al. Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 2007; 18: 269–74.

Tsukamoto H, Shibata K, Kajiyama H, et al. Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clin Exp Metastasis 2007; 24: 423–29.

Felix AS, Stone RA, Chivukula M, et al. Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression. Int J Cancer 2012; 131: E114–21.

Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of tumours of the female reproductive organs (IARC WHO Classification of Tumours). 4th Edition Series: IARC Press 2014; 307 p.

Iurchenko NP, Glushchenko NM, Buchynska LG. Аssessment of DNA status and peculiarities of expression of cyclins D1, e and transcription factor E2F1 in cells of epithelial endometrial tumors. Oncologyia 2019; 21: 423–37 (in Ukrainian).

Eckert F, Schilbach K, Klumpp L, et al. Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. Front Immunol 2018; 9: 30118. doi: 10.3389/fimmu.2018.03018.

Zhao H, Guo L, Zhao H, et al. CXCR4 over-expression and survival in cancer: A system review and meta-analysis. Oncotarget 2015; 6: 5022–40.

Werner RA, Kircher S, Higuchi T, et al. CXCR4-directed imaging in solid tumors. Front Oncol 2019; 9: 770.

Pein M, Insua-Rodríguez J, Hongu T, et al. Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nat Commun 2020; 11: 1–18.

Bertran E, Caja L, Navarro E, et al. Role of CXCR4/ SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 2009; 21: 1595–606.

Mushtaq M, Jensen L, Davidsson S, et al. The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4- dependent migration of cancer cells. Sci Rep 2018; 8: 2268.

Sarvaiya P, GuoD, UlasovІ, et al. Chemokines in tumor progression and metastasis. Oncotarget 2013; 12: 2171–85.

Batlle E, Massagué J. Transforming grown factor-β signaling in immunity and cancer. Immunity 2019; 50: 924–40.

Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF. Carcinogenesis 2007; 28: 267–79.

Boudot A, Kerdivel G, Habauzit D, et al. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 AND CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS ONE 2011; 6: e20898.

Nesinа ІP, Iurchenko NP, Brieieva OV, et al. Serum steroid hormone levels in endometrial cancer patients with different menstrual function and indicators of genomic instability. Оncologiya 2016, 18: 210–15 (in Ukrainian).

Wendt MK, Johanesen PA, Kang-Decker N, et al. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 2006; 25: 4986–97.

Chattopadhyay E, Singh R, Ray A,et al. Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer. Sci Rep 2016; 6: 32735.

Mirisola V, Zuccarino A, Bachmeier BE, et al. CXCL12/ SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer; 2009; 45: 2579–87.

Yan M, Jene N, Byrne D, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011; 13: R47.

Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 2018; 33: 463-79.e10.

Givel AM, Kieffer Y, Scholer-Dahirel A, et al. Mir 200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun 2018; 9: 1–20.

Ahirwar DK., Nasser MW, Ouseph MM, et al. Fibroblast derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation. Oncogene 2018; 37: 4428–42.

Zavyalova MV, Denisov EV, Tashireva LA, et al. Intravasation as a key step in cancer metastasis. Biochemistry 2019; 84: 972–84 (in Russian).

Sun Q, Zhou H, Binmadi NO, Basile JR. Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 2009; 284: 32066–74.

Ding D, Chu T, Liu H. Reciprocal crosstalk between endometrial carcinoma and mesenchymal stem cells via transforming growth factor-β/transforming growth factor receptor and C–X–C motif chemokine ligand 12/C–X–C chemokine receptor type 4 aggravates malignant phenotypes. Oncotarget 2017; 8: 115202–14.

Downloads

Published

26.05.2023

How to Cite

Buchynska, L., Movchan, O., & Iurchenko, N. (2023). Expression of chemokine receptor CXCR4 in tumor cells and content of CXCL12+-fibroblasts in endometrioid carcinoma of endometrium. Experimental Oncology, 43(2), 135–141. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16240

Issue

Section

Original contributions

Most read articles by the same author(s)